Merrimack Pharmaceuticals (NASDAQ: MACK) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Merrimack Pharmaceuticals to related businesses based on the strength of its earnings, valuation, risk, profitability, analyst recommendations, institutional ownership and dividends.
Earnings & Valuation
This table compares Merrimack Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Merrimack Pharmaceuticals||$144.27 million||-$151.74 million||-1.47|
|Merrimack Pharmaceuticals Competitors||$217.40 million||-$39.40 million||-63.33|
Merrimack Pharmaceuticals’ rivals have higher revenue and earnings than Merrimack Pharmaceuticals. Merrimack Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Merrimack Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merrimack Pharmaceuticals Competitors||-4,372.56%||-466.93%||-41.78%|
Institutional and Insider Ownership
50.1% of Merrimack Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 8.5% of Merrimack Pharmaceuticals shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings and target prices for Merrimack Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merrimack Pharmaceuticals Competitors||665||2523||6742||134||2.63|
Merrimack Pharmaceuticals presently has a consensus price target of $15.00, indicating a potential upside of 39.66%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.68%. Given Merrimack Pharmaceuticals’ higher possible upside, research analysts clearly believe Merrimack Pharmaceuticals is more favorable than its rivals.
Risk and Volatility
Merrimack Pharmaceuticals has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals’ rivals have a beta of 1.46, indicating that their average stock price is 46% more volatile than the S&P 500.
Merrimack Pharmaceuticals rivals beat Merrimack Pharmaceuticals on 7 of the 13 factors compared.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.